铂类仍可选时复发性上皮性卵巢癌患者的治疗
本文综述铂类仍可选时复发性上皮性卵巢癌的治疗,涵盖二次肿瘤细胞减灭术、化疗、新型治疗与维持治疗。分子特征有助于指导治疗决策;抗血管生成与PARP抑制剂维持治疗已成为标准治疗;免疫联合抗血管生成等新方案可能改变格局。
要点
- 上皮性卵巢癌分子特征对指导治疗决策至关重要。
- 抗血管生成治疗与PARP抑制剂维持治疗已成为标准治疗。
- 复发性上皮性卵巢癌治疗须结合患者个体与肿瘤因素。
核心结论
- 复发性上皮性卵巢癌的治疗正在快速变化,治疗须结合患者个体与肿瘤因素。
研究设计与样本
- 本文为文献综述,围绕铂类仍可选时复发性上皮性卵巢癌治疗的关键议题进行检索与汇总,并提出治疗流程。
主要发现
- 上皮性卵巢癌的分子特征对指导治疗决策至关重要。
- 二次肿瘤细胞减灭术的作用正通过妇科肿瘤组(GOG)213试验结果及DESKTOP III临床试验的预期结果进行评估。
- 化疗骨架相对未变,非铂类方案正在研究中。
- 抗血管生成治疗与聚(ADP-核糖)聚合酶(PARP)抑制剂维持治疗已成为标准治疗。
- 包括免疫治疗与抗血管生成药物在内的新型联合方案可能进一步改变当前格局。
临床怎么用
- 作者提出治疗流程以辅助复发性上皮性卵巢癌的治疗决策。
- 作者认为复发性上皮性卵巢癌的治疗须结合患者个体与肿瘤因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ovarian cancer remains the most deadly gynecologic cancer with the majority of patients relapsing within 3 years of diagnosis. Traditional treatment paradigms linked to platinum sensitivity or resistance are currently being questioned in the setting of new diagnostic methods and treatment options. DESIGN: Authors carried out review of the literature on key topics in treatment of recurrent epithelial ovarian cancer (EOC) when platinum is still an option; including secondary surgical cytoreduction, chemotherapy, novel treatment options, and maintenance therapy. A treatment algorithm is proposed. RESULTS: Molecular characterization of EOC is critical to help guide treatment decisions. The role of secondary cytoreductive surgery is currently being evaluated with results from Gynecologic Oncology Group (GOG) 213 and anticipated results from DESKTOP III clinical trials. Chemotherapy backbone has remained relatively unchanged but utilizing non-platinum-based regimens is under investigation. In addition, maintenance therapy with anti-angiogenic therapy and Poly (ADP-ribose) Polymerase (PARP) inhibitors has emerged as the standard of care. Novel combinations, including immunotherapy and anti-angiogenesis agents, may further change the current landscape. CONCLUSIONS: The treatment of recurrent EOC is rapidly changing. Clinical trial design will need to continue to evolve as many novel therapies move to the upfront setting. Ultimately, the treatment of patients with recurrent EOC must incorporate individual patient and tumor factors.
引用
- Buechel M, Herzog TJ, Westin SN, et al. Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option. Ann Oncol. 2019. PMID: 30887020. doi:10.1093/annonc/mdz104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。